Tegaserod has proven effective in inducing apoptosis and limiting tumor and metastasis development in mice inoculated with B16F10 melanoma by decreasing the expression of CD4+CD25+ T cells and hindering the PI3K/Akt/mammalian target of the rapamycin (mTOR) signaling pathway [134]. Here, AKT1 is linked to neoplasm.